

Medtronic



Symlicity™ Spyral  
renal denervation system



# Patient selection guide

## for the Symlicity™ blood pressure procedure

Are you considering the Symlicity procedure for your patients?  
Review patient selection criteria and patient examples to easily  
understand who may be the right fit.


# What is the Symplicity blood pressure procedure?

The Symplicity procedure is an innovative treatment option available to help patients with hypertension achieve blood pressure control, in addition to medications and lifestyle changes.<sup>1</sup>

The procedure uses the Symplicity Spyral™ renal denervation system, which is proven to deliver significant, safe, and sustained blood pressure reductions.<sup>2-5</sup>



Lifestyle changes



Medications




Symplicity™ blood pressure procedure

[See additional product information](#)

[View detailed clinical evidence](#)

## Recommended by societies

2024 European Society of Cardiology (ESC) Guidelines<sup>6</sup> and 2023 European Society of Hypertension (ESH) Guidelines<sup>7</sup> **recommend renal denervation** as a safe and effective complementary treatment option for patients with uncontrolled or resistant hypertension.



# Patient selection criteria

Based on the recent guidelines<sup>6,7</sup>, patients should be considered for renal denervation if they have office blood pressure **>140/90 mmHg** and meet **one of the following criteria**:



## Uncontrolled hypertension with:

- eGFR >40 ml/min/1.73m<sup>2</sup>
- can be on fewer than 3 antihypertensive drugs
- increased CV Risk



## Resistant hypertension with:

- eGFR >40 ml/min/1.73m<sup>2</sup>
- ≥3-drug combination (incl. a diuretic)\*



## Intolerant to medications:

- Regardless of medication burden

## Prior to the procedure, the following steps must occur<sup>6,7</sup>

- 1 **Confirm** uncontrolled out-of-office blood pressure (Home or Ambulatory BP)
- 2 Rule out **secondary causes** of hypertension
- 3 **Shared decision-making** process after assessment by a multidisciplinary team. **Patient preference** is an important consideration in the shared decision-making process as highlighted in guidelines<sup>6,7</sup>

1 in 3  
patients

would be willing to consider an interventional approach to manage hypertension versus an additional medication. (N = 400)<sup>8,9</sup>

\* Including a thiazide or thiazide-like diuretic



# Types of patients to consider for the SymPLICity procedure



## Cardiovascular comorbidities

### Mark

74-year-old male  
BP 178/96

On three medications

Mark is diligent about taking his medication, but his history of MI has made controlling his blood pressure more urgent. Mark has an eGFR of 50, and he is prediabetic.



## Multiple drugs, not controlled

### Estelle

68-year-old female  
BP 170/92

On five medications, including a diuretic

Estelle is on five medications, including one diuretic, and is using breakthrough hydralazine during the day. She's had two hospitalizations due to hypertension-related crises. The swelling in her legs from amlodipine also makes getting around challenging.



## Nonadherent due to side effects

### Henry

48-year-old male  
BP 154/105 with BP variability during nonadherent periods

Tried five medications; currently on one

Henry was diagnosed with hypertension at 38 when he started experiencing severe headaches. He's tried several medications he couldn't tolerate, and is currently on clonidine. Fatigue and other side effects of the medication, however, have taken a toll on the busy life as a father of three, and in turn have made him less adherent to his medication.





## Patient preference

### Gabriela

59-year-old female

BP 160/91

On three medications

Both of Gabriela's parents had hypertension, and one of them passed away from a stroke. Since then, she's been careful to remain active and maintain a good diet. She is frustrated about her blood pressure and anxiety is making her fearful of doing things she likes to do. She is open to any options to help improve her condition.



## Medication allergies

### Jake

36-year-old male

BP 160/95

Tolerates two medications after trying several others

Jake was diagnosed with high blood pressure one year ago. Despite trying diet and lifestyle modifications, he has struggled to get it under control. Jake is allergic to many of the medications available.

Results may vary. Case descriptions for educational purposes; not real patient cases.

## Refer your patient

Once you have identified your patient, you should refer them to an **experienced RDN center**.

**To find a clinic near you**, visit the Medtronic website or reach out to a Medtronic representative.



[Find a clinic near you](#)

# Access more resources

Explore additional tools to support patient selection for renal denervation, including educational videos, a handy pocket guide, and more.

## Access referral resources

1. Medtronic Symplicity Spyral multi-electrode renal denervation catheter Instructions for Use.
2. Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. *Lancet*. April 9, 2022;399(10234):1401-1410.
3. Mahfoud F, et al. *JACC Adv*. 2025 Mar;4(3):101606.
4. Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. *Lancet*. May 2, 2020;395(10234):1444-1451.
5. Kandzari D, Townsend RR, Kario K, et al. Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications. *J Am Coll Cardiol*. November 7, 2023;82(19):1809-1823.
6. McEvoy et al. *European Heart Journal* ehae178. <https://doi.org/10.1093/eurheartj/ehae178>
7. Mancia G. et al. *Journal of Hypertension* 2023, 41(12):1874-2071 DOI:10.1097/HJH.0000000000003480
8. Kandzari DE, Weber MA, Poulos C, et al. Patient Preferences for Pharmaceutical and Device-Based Treatments for Uncontrolled Hypertension: Discrete Choice Experiment. *Circ Cardiovasc Qual Outcomes*. January 2023;16(1):e008997.
9. Symplicity Spyral™ Renal Denervation System. Sponsor Presentation. Presented at: US FDA Circulatory Systems Devices Panel. August 23, 2023. Available at: <https://www.fda.gov/media/171691/download>. Accessed July 8, 2024.

The material on this website should not be considered the exclusive source of information, it does not replace or supersede information contained in the device manual(s). Please note that the intended use of a product may vary depending on geographical approvals. See the device manual(s) for detailed information regarding the intended use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For a MRI compatible device(s), consult the MRI information in the device manual(s) before performing a MRI. If a device is eligible for eIFU usage, instructions for use can be found at Medtronic's website [manuals.medtronic.com](https://manuals.medtronic.com). Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser. Medtronic products placed on European markets bear the CE mark and the UKCA mark (if applicable). For any further information, contact your local Medtronic representative.

## Medtronic

**Europe**  
Medtronic International Trading Sàrl.  
Route du Molliau 31  
Case postale  
CH-1131 Tolochenaz  
[www.medtronic.eu](https://www.medtronic.eu)  
Tel: +41 (0)21 802 70 00  
Fax: +41 (0)21 802 79 00

**[medtronic.eu/RDN](https://medtronic.eu/RDN)**

**United Kingdom/Ireland**  
Medtronic Limited  
Building 9  
Croxley Park  
Hatters Lane  
Watford  
Herts WD18 8WW  
[www.medtronic.co.uk](https://www.medtronic.co.uk)  
Tel: +44 (0)1923 212213  
Fax: +44 (0)1923 241004

17039347-en-gb-emea©2025 Medtronic. All rights reserved. Medtronic, Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. ™\*Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.  
For distribution only in markets where the Symplicity Spyral™ multi-electrode renal denervation catheter and Symplicity G3™ renal denervation RF generator have been approved. Not for distribution in the USA, Japan or France.